Tenaya Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Tenaya Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401 (gene therapy for PKP2-associated ARVC) in September 2026, supported by positive interim RIDGE-1 trial data. The company reported Q3 2026 cash of $66.8M (sufficient runway into Q4 2027), Q3 net loss of $18.9M ($0.08/share), and plans year-end data readouts and regulatory meetings for TN-201 and TN-401 to inform late-stage pivotal trial pathways; TN-301 Phase 2 initiation targeted for H2 2027.
Why this rating
RMAT designation is meaningful regulatory validation for lead program; cash runway into Q4 2027 is tight relative to $63.1M market cap. Event is operationally significant but clinical/regulatory outcomes remain uncertain.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.